Pulmatrix doses first subjects in Phase 1 trial of inhaled DHE (PUR3100) for acute migraine

Pulmatrix, Inc.

First five subjects dosed in Phase 1 trial of PUR3100, an inhaled formulation of dihydroergotamine (DHE) using iSPERSE technology.
Phase 1 is a double-dummy, double-blinded trial assessing safety, tolerability, and PK of 3 inhaled doses vs IV DHE in 24 healthy volunteers.
Data including safety, tolerability, and pharmacokinetics expected in Q4 2022 to guide dose selection for registration-enabling studies.
Dr. Margaret Wasilewski, CMO, cited oral inhalation as potentially more convenient than IV or nasal DHE with fewer side effects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.